Benjamin Custer, MD, MPH&TM

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Alnylam Pharmaceuticals
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Armata Pharmaceuticals
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Arrowhead Pharmaceuticals
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Beam Therapeutics
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    CRISR Therapeutics
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    CVS Health
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    GSK
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Ionis Pharmaceuticals
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Moderna Inc
    Date added:
    05/16/2025
    Date updated:
    06/02/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Pfizer Inc
    Date added:
    05/16/2025
    Date updated:
    06/02/2025

Pages

Return to 2025 JUNE CCSS S02: Multidrug-Resistant Organisms – Threats and Prevention Strategies